News
Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...
AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...
TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient ...
The Kintor Pharmaceutical Limited (the 'Company') is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.
Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.
18h
News Medical on MSNMassey becomes first U.S. site to enroll patients in global Phase 2a trial of first-in-class therapy for T-cell lymphomaVCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...
The trial demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate ...
Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...
Pasithea Therapeutics Corp. has announced the initiation of a Phase 1/1b clinical trial to assess its next-generation MEK inhibitor, PAS-004, for adults with neurofibromatosis type 1 (NF1) who ...
The MIRACLE study is a Phase 2B/3 clinical trial whereby data from the 2B portion will be combined with the Phase 3 portion for purposes of measuring its primary efficacy endpoint.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results